for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aquestive Therapeutics Inc

AQST.OQ

Latest Trade

5.15USD

Change

-0.25(-4.63%)

Volume

106,920

Today's Range

4.90

 - 

5.26

52 Week Range

1.41

 - 

10.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.40
Open
5.26
Volume
106,920
3M AVG Volume
23.87
Today's High
5.26
Today's Low
4.90
52 Week High
10.00
52 Week Low
1.41
Shares Out (MIL)
33.62
Market Cap (MIL)
171.80
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Aquestive Therapeutics Inc Earnings Release

Latest Developments

More

Aquestive Gets Complete Response Letter From FDA For Libervant Buccal Film For Management Of Seizure Clusters

Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial Of AQST-108

Aquestive Therapeutics Receives FDA Fast Track Designation For Aqst-108

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.

Industry

Biotechnology & Drugs

Contact Info

30 Technology Dr

WARREN, NJ

07059-5166

United States

+1.908.9411900

https://aquestive.com/

Executive Leadership

Santo Joseph Costa

Independent Chairman of the Board

Keith J. Kendall

President, Chief Executive Officer, Director

John D. Cochran

Vice Chairman of the Board

John T. Maxwell

Senior Vice President, Chief Financial Officer

Daniel Barber

Chief Operating Officer, Senior Vice President

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020(E)

0.0K
EPS (USD)

2018

-2.960

2019

-2.610

2020(E)

-1.508
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.90
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-134.09
Return on Equity (TTM)
-87.60

Latest News

Latest News

BRIEF-Aquestive Files IND For Pharmacokinetic Clinical Trials Of Aqst-108 For Anaphylaxis Treatment

* AQUESTIVE THERAPEUTICS FILES IND FOR PHARMACOKINETIC CLINICAL TRIALS OF AQST-108 (SUBLINGUAL FILM FORMULATION DELIVERING SYSTEMIC EPINEPHRINE) FOR ANAPHYLAXIS TREATMENT

BRIEF-Aquestive Says Expect To Receive Between Up To $100 Million Of Non-Dilutive Capital From Monetization Of Royalty Stream

* AQUESTIVE THERAPEUTICS ADVANCES ROYALTY MONETIZATION PLAN AS SUNOVION PHARMACEUTICALS’ APOMORPHINE SUBLINGUAL FILM THERAPY RECEIVES FDA APPROVAL

BRIEF-Aquestive Therapeutics Reports First Quarter 2020 Financial Results And Provides Business Update Aqst-108 And Libervant Remain On Track

* AQUESTIVE THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE: AQST-108 AND LIBERVANT REMAIN ON TRACK

BRIEF-Aquestive Therapeutics Was Granted A $4.8 Mln Loan On April 17, 2020 Under Paycheck Protection Program

* AQUESTIVE THERAPEUTICS INC - WAS GRANTED A $4.8 MILLION LOAN ON APRIL 17, 2020 UNDER PAYCHECK PROTECTION PROGRAM Source text: [https://bit.ly/2xLaSgh] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Aquestive Therapeutics Says Have Not Sold Any Shares Under Equity Distribution Agreement

* AQUESTIVE THERAPEUTICS - AS OF MARCH 11, HAVE NOT SOLD ANY SHARES UNDER EQUITY DISTRIBUTION AGREEMENT - SEC FILING Source: (http://bit.ly/2ILqPVi) Further company coverage:

BRIEF-Aquestive Therapeutics Reports Q4 Revenue Of $16.4 Million

* AQUESTIVE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

FDA approves Aquestive's ALS treatment

The U.S. Food and Drug Administration on Friday approved http://bit.ly/2pIFzi5 Aquestive Therapeutics' treatment for neurological disorder amyotrophic lateral sclerosis (ALS).

REFILE-FDA approves Aquestive's ALS treatment

The U.S. Food and Drug Administration on Friday approved Aquestive Therapeutics' treatment for neurological disorder amyotrophic lateral sclerosis (ALS).

FDA declines to approve Aquestive's Viagra rival

Aquestive Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its erectile dysfunction treatment and sought additional data.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up